Cooperative Agreement UG3AR079297

This Project Grant award of $170,490 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research to develop and validate computable phenotypes for pediatric atopic dermatitis and compare the effectiveness and safety of dupilumab versus methotrexate for treating this condition. The funding will enable The Johns Hopkins University to utilize electronic health...

This Cooperative Agreement from the National Institutes of Health (NIH) under the 21st Century Cures Act: Regenerative Medicine Initiative (CFDA 93.370) provides $538,200.00 to The Regents of the University of Colorado, doing business as the University of Colorado-Denver, to conduct a Phase 1 pilot study on the safety and efficacy of induced pluripotent stem cell (iPSC)-based therapy for recessive dystrophic epidermolysis bullosa (RDEB). The study will evaluate the use of genetically...

This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $343,904 to The Regents of the University of California, San Francisco to investigate transcriptional abnormalities in skin-resident T cells as potential biomarkers for atopic dermatitis in Asian and Hispanic genetic backgrounds. The research aims to validate an abnormal atopic T...

This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $198,782.00 to Duke University to develop 3D human reconstructed epidermis (RHE) cultures with CRISPR/Cas9 gene knockouts. The goal is to enable investigation of interactions between the skin microbiome and skin cell populations. The RHE cultures will be colonized with commensal and...

This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) provides $295,294 to Biotherapeutics, Inc. for the development of a novel first-in-class topical immunoregulatory therapeutic for the treatment of plaque psoriasis. The key objectives are to: 1) evaluate the permeability and long-term stability of the topical drug product formulation, 2) compare the...

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $628,968 project grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to The Regents of the University of California, San Francisco (UCSF) to define and treat genetic abnormalities in psoriasis/atopic dermatitis-overlap dermatoses. The project aims to use high-resolution, quantitative biomarkers to understand the etiology of these "PSO-AD" rashes and determine if they...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,297,775 Cooperative Agreement under the Allergy and Infectious Diseases Research program (CFDA 93.855) to National Jewish Health in Denver, Colorado. The funding will support a research project titled "SUNBEAM Birth Cohort: Deciphering the Role of Early Life Skin Dysfunction in Development of the Allergic March." The project aims to evaluate whether early-life skin pathobiology leads to the development of...

This Project Grant award of $563,028 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports the development of engineered gamma delta T cells for systemic correction of recessive dystrophic epidermolysis bullosa (RDEB). The grantee, Kommodo Therapeutics LLC, aims to engineer gamma delta T cells to produce high levels of the collagen type VII protein, which is deficient...

This Project Grant award from the National Center for Advancing Translational Sciences (CFDA 93.350) provides $176,500.00 to the University of Washington for the period of July 1, 2024 to June 30, 2025. The goal of the project is to delineate the pathogenic effects of ATP2C1 loss-of-function in human keratinocytes and organotypic epidermis to identify therapeutic strategies for Hailey-Hailey Disease (HHD), a rare skin blistering disorder. The research aims to determine how SPCA1 deficiency...

This SBIR Phase I award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $295,924 to Biotherapeutics, Inc. to develop a novel topical therapeutic for the treatment of psoriasis. The key objectives are to: 1) characterize the therapeutic efficacy of the new treatment in a mouse model of psoriasis, 2) develop a topical drug product formulation and test its...